IQV earnings analysis
What we found in IQV's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
IQVIA delivered solid Q2 top-line growth, with revenue up 8.7% to $4.368 billion and both newly recast segments growing approximately 9%. Segment profitability improved, but consolidated GAAP operating income remained $506 million as restructuring costs rose to $63 million and operating margin fell to 11.6% from 12.6%. Operating cash flow strengthened to $1.176 billion for the first half, although the capital structure remains leveraged with $16.081 billion of indebtedness.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue growth accelerated to 8.7%
- Q2 revenue rose $351 million, or 8.7%, year over year to $4.368 billion. Constant-currency growth was approximately $343 million, or 8.5%, with both operating segments contributing.
- Commercial Solutions profit outgrew sales
- Commercial Solutions grew revenue 8.6% to $1.793 billion and segment profit 10.6% to $419 million. Management attributed constant-currency growth primarily to patient solutions and, to a lesser extent, commercial engagement services.
- R&D Solutions delivered broad growth
- R&D Solutions revenue increased 8.8% to $2.575 billion and segment profit rose 11.2% to $526 million, driven primarily by volume-related growth in clinical services and lab testing.
- Backlog supports near-term revenue visibility
- R&D contracted backlog increased $0.2 billion from $34.0 billion at December 31, 2025 to $34.2 billion at June 30, 2026; management expects approximately $9.2 billion to convert to revenue in the next 12 months.
- Operating cash flow improved
- Six-month operating cash flow rose $165 million year over year to $1.176 billion, aided by $106 million more cash from other operating assets and liabilities, $89 million higher cash-related net income, and $40 million from receivables and unbilled services.
- Buyback authorization remains substantial
- The Board added $2.0 billion to the repurchase authorization in May, and the company repurchased 5.5 million shares for $950 million in the first six months of 2026. Remaining authorization was $2.819 billion at June 30.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Margin pressure and elevated restructuring
- GAAP operating income was flat at $506 million despite $351 million of revenue growth, reducing operating margin to 11.6% from 12.6% a year earlier. Restructuring expense nearly doubled to $63 million from $32 million, and management expects restructuring actions to continue through 2026 and into 2027.
- High debt burden and rising interest cost
- Total indebtedness was $16.081 billion at June 30, 2026, while quarterly interest expense increased $15 million year over year to $197 million. Cash declined $71 million from $1.980 billion at year-end to $1.909 billion.
- Overhead grew faster than revenue
- Cost of revenue held at 67.1% of sales, but SG&A increased 12.8% to $574 million and rose to 13.1% of revenue from 12.7%. Management cited compensation-related costs, including stock-based compensation, as a driver.
- No new risk-factor updates; facility capacity matters
- Item 1A states there were no material changes to risk factors from the 2025 Form 10-K. Nonetheless, liquidity depends materially on operating cash flow and financing capacity: only $1.195 billion remained available under the revolving credit facility and no additional revolving loans were available under the receivables financing facility at June 30, 2026.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $1.53
- Gross margin
- 32.9%
- Operating margin
- 11.6%
- Segment
- Commercial Solutions revenue: $1.793 billion, up $142 million / 8.6% year over year; segment profit: $419 million, up $40 million / 10.6%.
- Segment
- Research & Development Solutions revenue: $2.575 billion, up $209 million / 8.8% year over year; segment profit: $526 million, up $53 million / 11.2%.
What they said about what is next.
The 10-Q MD&A does not provide quantitative revenue or EPS guidance. Management states that available cash, operating cash flow, and facility access are expected to fund operating needs, capex, contractual obligations, and debt obligations for at least the next 12 months; R&D Solutions expects approximately $9.2 billion of its $34.2 billion backlog to convert to revenue over the next 12 months.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 5, 2026
- IQVIA Holdings Inc. reported strong Q1 2026 results, with revenues of $4.15 billion, a year-over-year increase of 8.4%, and EPS of $2.90, exceeding analysts' estimates. The company showcased a positive outlook with…
- 10-K · February 17, 2026
- IQVIA delivered 2025 revenue of $16,310 million, up 5.9% vs. 2024, driven by Technology & Analytics Solutions (+7.6% to $6,626M) and Research & Development Solutions (+4.3% to $8,896M). Operating income was $2,182M…
- 10-Q · May 6, 2025
- IQVIA reported Q1 revenue of $3,829 million, up $92 million (+2.5%) year-over-year but down versus the prior quarter. Gross margin contracted to 33.9% and operating margin to ~13.0%, while diluted EPS fell to $1.40.…
- 10-Q · October 31, 2024
- IQVIA reported third-quarter revenue of $3,896 million, up $160 million (+4.3%) versus the prior year, with income from operations rising to $550 million and operating margin expanding to 14.1%. Diluted EPS declined to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing IQV makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever